-
公开(公告)号：US11980669B2
公开(公告)日：2024-05-14
申请号：US16807375
申请日：2020-03-03
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
CPC classification number: A61K47/6889 , A61K38/05 , A61K47/68 , A61K47/6817 , A61K47/6851 , A61K47/6855 , C07K16/00 , C07K16/30 , C07K2317/14 , C07K2317/40 , C07K2317/526 , C07K2317/55 , C07K2317/94
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
公开(公告)号：US20200055930A1
公开(公告)日：2020-02-20
申请号：US16541817
申请日：2019-08-15
Applicant: Pfizer Inc.
Inventor： Kevin Charles Beaumont , Danna M. Breen , Matthew Allister Lambert , Jeffrey Raymond Chabot , Tao He , Ksenya Shchors , James R. Apgar
Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
-
公开(公告)号：US12227564B2
公开(公告)日：2025-02-18
申请号：US17816484
申请日：2022-08-01
Applicant: Pfizer Inc.
Inventor： Kevin Charles Beaumont , Danna M. Breen , Matthew Allister Lambert , Jeffrey Raymond Chabot , Tao He , Ksenya Shchors , James R. Apgar
Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
-
Patent Agency Ranking
公开(公告)号：US20220380448A1
公开(公告)日：2022-12-01
申请号：US17816484
申请日：2022-08-01
Applicant: Pfizer Inc.
Inventor： Kevin Charles Beaumont , Danna M. Breen , Matthew Allister Lambert , Jeffrey Raymond Chabot , Tao He , Ksenya Shchors , James R. Apgar
Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
-
公开(公告)号：US20200230256A1
公开(公告)日：2020-07-23
申请号：US16807375
申请日：2020-03-03
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
公开(公告)号：US10653794B2
公开(公告)日：2020-05-19
申请号：US15748268
申请日：2016-08-09
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
公开(公告)号：US20190030183A1
公开(公告)日：2019-01-31
申请号：US15748268
申请日：2016-08-09
Applicant: PFIZER INC.
Inventor： Xiaotian Zhong , Amarnauth Shastrie Prashad , Ronald William Kriz , Tao He , Will Somers , Wenge Wang , Leo Joseph Letendre
Abstract: An antibody production process in mammalian cells in which engineered unpaired cysteine residues are post-translationally modified and capped with particular chemical entities, which capped antibodies are well suited to further site-specific conjugation steps to form antibody-drug conjugates (ADCs) or protein drug conjugates; ADCs produced using these capped antibodies including in particular ADCs formed by the selective reduction of the capped antibodies' cysteine residues, and ADCs formed using chemical handles such as aldehyde/azide/alkyne biorthogonal groups, which permit additional drug conjugation chemistry; and uncapped antibodies produced by cells in low cysteine, cysteine and glutathione media, and ADCs produced via direct conjugation to these uncapped antibodies.
-
公开(公告)号：US11566066B2
公开(公告)日：2023-01-31
申请号：US16541817
申请日：2019-08-15
Applicant: Pfizer Inc.
Inventor： Kevin Charles Beaumont , Danna M. Breen , Matthew Allister Lambert , Jeffrey Raymond Chabot , Tao He , Ksenya Shchors , James R. Apgar
Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to GDF15, as well as methods and uses for the antibodies.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.019 seconds)
